Jefferies analyst Andrei Andon-Ionita noted that pouch sales have become a significant factor in the valuation of BAT and PMI, with regulatory risks initially considered to be minimal. This highlights a disturbing trend: the normalization of nicotine pouch use as a seemingly harmless alternative, despite the potential for addiction and long-term health consequences. Andon-Ionita's statement underscores the importance of scrutinizing industry-sponsored research and challenging the narrative that nicotine pouches are a risk-free alternative.

Nicotine pouches are the fastest-growing nicotine product in the U.S., with millions of users. In 2025, PMI sold 794 million cans of Zyn in the U.S., more than double its 2023 sales figures. This exponential growth is alarming, as it suggests that nicotine pouches are not merely a replacement for traditional cigarettes but are also attracting new users, potentially including young people who would not have otherwise used tobacco products.

The FDA had planned to expedite the approval process for these applications through a pilot program, with decisions expected by the end of 2025. Six pouches under Altria’s on! PLUS label received authorization in December. However, the remaining applications for four other pouch brands remain pending, a testament to the agency's commitment to thorough evaluation.

Sources familiar with the FDA's process indicate that agency reviewers are exercising caution due to scientific evidence that was not as conclusive as expected. Concerns specifically involve potential risks to youth and non-users, including the risk of addiction for adults who do not currently smoke. This reinforces the need for independent research and a critical assessment of industry-funded studies.

In response to inquiries from Reuters, the FDA stated that the applications within the pilot program are progressing faster than most others. However, the agency declined to comment on specific concerns related to risks to youth or new users. The FDA maintains that nicotine products are highly addictive and not risk-free, particularly for adolescents, as nicotine can harm developing brains. This cautionary message must be amplified to counteract the industry's efforts to normalize nicotine use among young people.

Despite the risks, the FDA acknowledged that nicotine pouches are generally less harmful than traditional cigarettes. The agency stated that scientific data suggests smokers who completely switch to pouches may experience reduced health risks. However, this does not negate the potential for addiction and the need for comprehensive regulation. The FDA is currently weighing evidence regarding the effectiveness of each pouch product in facilitating the switch from smoking against information on potential risks, including data from its own surveys on pouch usage among middle and high school students. This rigorous evaluation process is essential to protect public health and prevent the proliferation of harmful nicotine products.

The FDA’s annual survey indicates that nicotine pouch usage among middle and high school students remains low, but it has increased in recent years. This upward trend should serve as a wake-up call. The FDA must prioritize prevention efforts, including public awareness campaigns and stricter regulations on marketing and sales, to protect young people from the dangers of nicotine addiction.

The FDA's cautious approach to nicotine pouches is a vital step in safeguarding public health, particularly the health of vulnerable youth, from the predatory tactics of Big Tobacco, while highlighting the need for stronger regulations and independent research to counteract corporate influence.